Follow-up of IgD-κ multiple myeloma by monitoring free light chains and total heavy chain IgD: A case report

De Santis,Elena; Masi,Serena; Cordone,Iole; Pisani,Francesco; Zuppi,Cecilia; Mattei,Fabrizio; Conti,Laura; Cigliana,Giovanni

doi:10.3892/ol.2016.4869

September-2016 Volume 12 Issue 3

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

September-2016 Volume 12 Issue 3

Full Size Image

Case Report Open Access

Follow-up of IgD-κ multiple myeloma by monitoring free light chains and total heavy chain IgD: A case report

Authors:
- Elena De Santis
- Serena Masi
- Iole Cordone
- Francesco Pisani
- Cecilia Zuppi
- Fabrizio Mattei
- Laura Conti
- Giovanni Cigliana
View Affiliations / Copyright

Affiliations: Clinical Pathology Unit, Italian National Cancer Institute ‘Regina Elena’, I‑00144 Rome, Italy, Hematology and Stem Cell Transplantation Unit, Italian National Cancer Institute ‘Regina Elena’, I‑00144 Rome, Italy, Department of Laboratory Medicine and Diagnostics, University Hospital Agostino Gemelli, I‑00168 Rome, Italy, Department of Hematology, Oncology and Molecular Medicine, National Institute of Health, I‑00161 Rome, Italy

Copyright: © De Santis et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Pages: 1884-1888
|
Published online on: July 15, 2016

https://doi.org/10.3892/ol.2016.4869
Expand metrics +

Abstract

Immunoglobulin (Ig)D‑κ multiple myeloma (MM) is a rare neoplastic disease characterized by an aggressive and rapidly progressing course, which constitutes only a very small proportion of all MM cases. In the present report, the clinical case of a 51‑year‑old Caucasian woman diagnosed with IgD‑κ MM is described. The patient underwent different chemotherapeutic treatments subsequently to a single autologous stem cell transplantation. Despite the inherent difficulty of monitoring IgD levels and performing serum immunofixation electrophoresis, the clinical outcome of the patient was almost uniquely monitored by measuring the levels of κ and λ free light chains (FLCs) and total heavy chain IgD. The data suggest the non‑invasive potential and usefulness of FLCs evaluation for early detection of stringent complete remission, follow‑up and early detection of disease relapse. In addition, this diagnostic procedure has successfully been employed for the therapeutic monitoring of the present patient, and may represent a very helpful, non‑invasive tool for the follow‑up of IgD myeloma patients without the requirement of serial bone marrow aspirate.

View Figures

View References

1	Geng C, Liu N, Yang G, Liu A, Leng Y, Wang H, Li L, Wu Y, Li Y and Chen W: Retrospective analysis of 264 multiple myeloma patients. Oncol Lett. 5:707–713. 2013.PubMed/NCBI
2	Raab MS, Podar K, Breitkreutz I, Richardson PG and Anderson KC: Multiple myeloma. Lancet. 374:324–339. 2009. View Article : Google Scholar : PubMed/NCBI
3	Pandey S and Kyle RA: Unusual myelomas: A review of IgD and IgE variants. Oncology (Williston Park). 27:798–803. 2013.PubMed/NCBI
4	Paiva B, Martinez-Lopez J, Vidriales MB, Mateos MV, Montalban MA, Fernandez-Redondo E, Alonso L, Oriol A, Teruel AI, de Paz R, et al: Comparison of immunofixation, serum free light chain and immunophenotyping for response evaluation and prognostication in multiple myeloma. J Clin Oncol. 29:1627–1633. 2011. View Article : Google Scholar : PubMed/NCBI
5	Sinclair D: IgD myeloma: Clinical, biological and laboratory features. Clin Lab. 48:617–622. 2002.PubMed/NCBI
6	Richardson PG, Laubach J, Paba-Prada C and Anderson KC: IgD and IgE variants of myeloma: Valuable insights and therapeutic opportunities. Oncology (Williston Park). 27:803–804. 2013.PubMed/NCBI
7	Ferrero S, Drandi D, Mantoan B, Ghione P, Omede P and Ladetto M: Minimal residual disease detection in lymphoma and multiple myeloma: Impact on therapeutic paradigms. Hematol Oncol. 29:167–176. 2011. View Article : Google Scholar : PubMed/NCBI
8	Ozaki S, Harada T, Saitoh T, Shimazaki C, Itagaki M, Asaoku H, Kuroda Y, Chou T, Yoshiki Y, Suzuki K, et al: Survival of multiple myeloma patients aged 65–70 years in the era of novel agents and autologous stem cell transplantation. A multicenter retrospective collaborative study of the japanese society of myeloma and the european myeloma network. Acta Haematol. 132:211–219. 2014. View Article : Google Scholar : PubMed/NCBI
9	Pisani F, Petrucci MT, Giannarelli D, Bongarzoni V, Montanaro M, De Stefano V, La Verde G, Gentilini F, Levi A, Za T, et al: IgD multiple myeloma a descriptive report of 17 cases: Survival and response to therapy. J Exp Clin Cancer Res. 31:172012. View Article : Google Scholar : PubMed/NCBI
10	Fu C, Wang J, Xin X, Liu H, Xue S, Ma X, Jin Z, Sun A, Qiu H and Wu D: Therapeutic effects of autologous hematopoietic stem cell transplantation in multiple myeloma patients. Exp Ther Med. 6:977–982. 2013.PubMed/NCBI
11	Morabito F, Gentile M, Ciolli S, Petrucci MT, Galimberti S, Mele G, Casulli AF, Mannina D, Piro E, Pinotti G, et al: Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: A retrospective study of Italian Myeloma Network GIMEMA. Eur J Haematol. 84:223–228. 2010. View Article : Google Scholar : PubMed/NCBI
12	Palumbo A, Rajkumar SV, San Miguel JF, Larocca A, Niesvizky R, Morgan G, Landgren O, Hajek R, Einsele H, Anderson KC, et al: International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation. J Clin Oncol. 32:587–600. 2014. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Follow-up of IgD-κ multiple myeloma by monitoring free light chains and total heavy chain IgD: A case report

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Related Articles